相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children
M. F. Ara-Montojo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Antimicrobial Activity of Ceftazidime-Avibactam Against Contemporary Pathogens From Urinary Tract Infections and Intra-abdominal Infections Collected From US Children During the 2016-2019 INFORM Surveillance Program
Lynn-Yao Lin et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2021)
Pivotal Role of Translation in Anti-Infective Development
Lena E. Friberg
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam
Jianguo Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Carbapenem-Resistant Gram-Negative Bacterial Infections in Children
David Aguilera-Alonso et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme
Karen Cheng et al.
DRUG SAFETY (2020)
Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteria
Helio S. Sader et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2020)
Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children
Kathleen Chiotos et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2020)
Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
Jianguo Li et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points
Aatoni Torres et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial
John S. Bradley et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2019)
Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children >= 3 Months to < 18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial
John S. Bradley et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2019)
Paediatric extrapolation: A necessary paradigm shift
Cecile Ollivier et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view
Laura Folgori et al.
BMJ OPEN (2019)
Incidence and Outcomes of Infections Caused by Multidrug-Resistant Enterobacteriaceae in Children, 2007-2015
Sharon B. Meropol et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2018)
Avibactam Pharmacokinetic/Pharmacodynamic Targets
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015)
Helio S. Sader et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2018)
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis
Paola Pansa et al.
DRUGS (2018)
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
Xinyu Qin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients
John S. Bradley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development
Yeruk Mulugeta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options
Elizabeth Cerceo et al.
MICROBIAL DRUG RESISTANCE (2016)
Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects
Shampa Das et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Randomized, Placebo-Controlled Study to Assess the Impact on QT/QTc Interval of Supratherapeutic Doses of Ceftazidime-Avibactam or Ceftaroline Fosamil-Avibactam
Shampa Das et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential
Karthick Vishwanathan et al.
DRUG METABOLISM AND DISPOSITION (2014)
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
Z. Aktas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs
Julia Dunne et al.
PEDIATRICS (2011)
Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae
S. Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Measurement and Estimation of GFR in Children and Adolescents
George J. Schwartz et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
Therese Stachyra et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
New Equations to Estimate GFR in Children with CKD
George J. Schwartz et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Human renal function maturation: a quantitative description using weight and postmenstrual age
Malin M. Rhodin et al.
PEDIATRIC NEPHROLOGY (2009)
Community-acquired complicated intra-abdominal infections in children hospitalized during 1995-2004 at a paediatric surgery department
Nitza Newman et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2009)
Acute appendicitis risks of complications: Age and Medicaid insurance
SL Bratton et al.
PEDIATRICS (2000)
分享论文
